Barbara E White

US Patent:

20060009452, Jan 12, 2006

Filed:

Jun 3, 2005

Appl. No.:

11/143707

Inventors:

Sergei Atamas - Columbia MD, US
Irina Luzina - Columbia MD, US
Barbara White - Finksburg MD, US

International Classification:

A61K 31/5377

US Classification:

514232800

Abstract:

The present invention relates to methods of treating, preventing or preventing the progression of fibrosis comprising inhibiting the actions of pulmonary and activation-regulated chemokine (PARC) or at least one of its downstream effector molecules, such as Sp1 transcription factor and protein kinase C-alpha (PKCα). The present invention also relates to methods of screening and/or identifying compounds useful for the treatment of fibrosis comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα. The present invention also relates to methods of screening and/or identifying compounds that prevent or inhibit collagen deposition comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα.

US Patent:

20100143373, Jun 10, 2010

Filed:

Dec 6, 2007

Appl. No.:

12/517334

Inventors:

Barbara White - Finksburg MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241581

Abstract:

The present invention relates to a method of treating SLE in a human subject comprising administration of an anti-interferon α antibody.

US Patent:

20110287022, Nov 24, 2011

Filed:

Jun 19, 2009

Appl. No.:

12/999626

Inventors:

Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Boston MA, US
Peter Kiener - Potomac MD, US
Barbara White - Finksburg MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C40B 30/04
A61P 29/00
A61P 17/06
A61P 19/02
G01N 33/53
C12Q 1/02

US Classification:

4241581, 436501, 506 9, 435 29

Abstract:

The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders.

US Patent:

20120251546, Oct 4, 2012

Filed:

Sep 2, 2010

Appl. No.:

13/393616

Inventors:

Brandon Higgs - Gaithersburg MD, US
Wei Zhu - Boyds MD, US
Chris Morehouse - Middletown MD, US
Barbara White - Finksburg MD, US
Bahija Jallal - Potomac MD, US
Yihong Yao - Boyds MD, US

Assignee:

MEDIMMUNE LLC - GAITHERBURG MD

International Classification:

A61K 39/395
G06F 19/00
G01N 21/64

US Classification:

4241421, 435 611, 4241581, 4241721, 702 19

Abstract:

The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

US Patent:

20160024205, Jan 28, 2016

Filed:

Oct 6, 2015

Appl. No.:

14/876549

Inventors:

- Gaithersburg MD, US
Wei Zhu - Gaithersburg MD, US
Chris Morehouse - Middletown MD, US
Barbara White - Finksburg MD, US
Bahija Jallal - Potomac MD, US
Yihong Yao - Boyds MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

C07K 16/24
C12Q 1/68

Abstract:

The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

US Patent:

20150191788, Jul 9, 2015

Filed:

Mar 18, 2015

Appl. No.:

14/662134

Inventors:

- GAITHERSBURG MD, US
WEI ZHU - GAITHERSBURG MD, US
CHRIS MOREHOUSE - MIDDLETOWN MD, US
BARBARA WHITE - FINKSBURG MD, US
BAHIJA JALLAL - POTOMAC MD, US
YIHONG YAO - BOYDS MD, US

International Classification:

C12Q 1/68

Abstract:

The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.